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ABSTRACT 
 
Background: Long QT syndrome (LQTS) is a rare genetic disorder and a major preventable 
cause of sudden cardiac death in the young. A causal rare genetic variant with large effect size 
is identified in up to 80% of probands (genotype positive) and cascade family screening shows 
incomplete penetrance of genetic variants. Furthermore, a proportion of cases meeting 
diagnostic criteria for LQTS remain genetically elusive despite genetic testing of established 
genes (genotype negative). These observations raise the possibility that common genetic 
variants with small effect size contribute to the clinical picture of LQTS. This study aimed to 
characterize and quantify the contribution of common genetic variation to LQTS disease 
susceptibility. 
 
Methods: We conducted genome-wide association studies (GWAS) followed by transethnic 
meta-analysis in 1,656 unrelated LQTS patients of European or Japanese ancestry and 9,890 
controls to identify susceptibility single nucleotide polymorphisms (SNPs). We estimated the 
SNP heritability (h2SNP) of LQTS and tested the genetic correlation between LQTS susceptibility 
and other cardiac traits. Furthermore, we tested the aggregate effect of the 68 SNPs previously 
associated with QTc in the general population using a polygenic risk score (PRSQT).  
 
Results: Genome-wide association analysis identified three loci associated with LQTS at 
genome-wide statistical significance (P<5x10-8) near NOS1AP, KCNQ1 and KLF12, and one 
missense variant in KCNE1 (p.Asp85Asn) at the suggestive threshold (P<10-6). Heritability 
analyses showed that ~15% of variance in overall LQTS susceptibility was attributable to 
common genetic variation (h2SNP 0.148; standard error [SE] 0.019). LQTS susceptibility showed 
a strong genome-wide genetic correlation with the QT interval in the general population 
(rg=0.40, P=3.2x10-3). PRSQT was greater in LQTS cases compared to controls (P<10-13), and 
notably, among LQTS patients PRSQT was greater in genotype negative compared to genotype 
positive patients (P<0.005). 
 6 
Conclusion: This work establishes an important role for common genetic variation in 
susceptibility to LQTS. We demonstrate overlap between genetic control of the QT interval in 
the general population and genetic factors contributing to LQTS susceptibility. Using polygenic 
risk score analyses aggregating common genetic variants that modulate the QT interval in the 
general population, we provide evidence for a polygenic architecture in genotype negative 
LQTS. 
 
Key words: long QT syndrome, genome-wide association study, polygenic risk score, 
heritability, QT-interval 
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What is new? 
• A genome-wide association study in Long-QT syndrome (LQTS) patients establishes 
and quantifies the role of common genetic variation in susceptibility to LQTS. 
• Genetic overlap exists between control of QT-interval in the general population and 
susceptibility to LQTS. 
• Polygenic risk score analyses based on common genetic variants that modulate the 
QT-interval in the general population provide evidence for a polygenic architecture in 
LQTS patients that remain genetically elusive despite genetic testing of established 
genes (i.e. genotype negative). 
 
What are the clinical implications? 
• These findings enhance the understanding of the genetic basis of LQTS and 
underscore the genetic relationship between QT-interval in the general population and 
susceptibility to LQTS. 
• Increasing burden of QT-prolonging common variants is associated with higher 
susceptibility for LQTS. 
• Polygenicity in genotype negative LQTS patients implies that risk is not primarily 
attributable to one genetic factor inherited from one of the biological parents as is the 
case for autosomal dominant LQTS.  
• Future clinical utility of genetic testing based on polygenic inheritance necessitates the 
availability of polygenic risk scores with high discriminative capacity. 
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INTRODUCTION 
 
Long QT syndrome (LQTS) is a rare inherited disorder of ventricular repolarization 
characterized by prolongation of the QT interval on the electrocardiogram (ECG).[1,2] LQTS 
has a prevalence of approximately 1 in 2500, and is a major and often preventable cause of 
sudden cardiac death (SCD) in the young.[3,4] Multiple genes have been implicated in LQTS 
and clinical genetic testing is now performed to identify causative rare genetic variants.[5] 
Disease-causing variants (i.e. mutations) in the three major LQTS genes, i.e. KCNQ1 (LQT1), 
KCNH2 (LQT2) and SCN5A (LQT3), account for up to 80% of LQTS cases overall and >95% 
of genotype positive LQTS.[2] 
Studies in families with multiple mutation carriers have shown that disease penetrance 
(proportion of carriers that manifest with a prolonged QT interval) can be low,[6–8] and that 
among those with disease manifestations, there can be broad variability in the types of 
symptoms and severity thereof (variable expression).[2,6–8] These observations suggest that, 
like other Mendelian disorders, allocating the disease in the individual patient exclusively to a 
rare variant at a single locus (i.e. monogenetic) might be an oversimplification of biological 
phenomena. It is likely that a combination of genetic and non-genetic modifying factors 
underlies this clinical variability. A comprehensive knowledge of such risk factors that affect 
penetrance and expressivity of disease-causing variants in LQTS will improve the predictive 
accuracy of genetic testing in the individual patient and enable personalized clinical 
interventions. While many clinical risk factors such as sex, hypokalaemia, or bradyarrhythmia, 
have been implicated as modulators of the clinical manifestations of LQTS[9], modulatory 
genetic factors remain largely unexplored with the exception of a few proof-of-concept studies 
using a candidate gene approach.[10–14] 
Besides variability in disease manifestations among carriers of pathogenic variants, an 
outstanding issue in LQTS is the fact that in ~20% of patients, an underlying causal rare genetic 
variant remains unidentified after extensive panel-based genetic testing.[15] This complicates 
cascade screening in families and the pre-symptomatic identification of affected relatives. 
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Although a small proportion of such genotype negative LQTS patients could have a yet 
unknown Mendelian defect, another possibility is that a more complex inheritance pattern 
underlies the disorder in a subset of these patients. 
Previous work has shown that genome-wide association study (GWAS) comparing 
cases of a rare arrhythmia syndrome to unaffected controls can define modulators of disease 
susceptibility and suggest a polygenic etiology.[16] We report here a GWAS in ~1,700 
unrelated LQTS patients of European or Japanese ancestry, identifying common genetic 
variants implicated in LQTS disease susceptibility, and providing a quantification of the 
contribution of common genetic variants to LQTS predisposition. Using polygenic risk score 
analyses aggregating common genetic variants that modulate the QT interval in the general 
population, we provide evidence for a polygenic architecture in genotype negative LQTS. 
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METHODS 
 
The summary statistics generated in this study are available from the corresponding author 
upon request. 
 
Study population 
We established an international consortium allowing recruitment of 1,781 unrelated LQTS 
patients: 1,344 cases of European ancestry from 23 referral centres in Europe, New Zealand 
and North America, as well as 437 patients of East Asian ancestry from 4 referral centres in 
Japan (Table I in the Supplement). Included unrelated individuals were probands (97%) 
except when DNA was not available, in which case one other affected family member was 
included instead. Included LQTS patients had a clinical diagnosis of LQTS[5] and were 
classified as “genotype positive” if they carried a single rare variant in one of the three 
established major LQTS genes [KCNQ1 (LQT1), KCNH2 (LQT2) and SCN5A (LQT3)], or 
“genotype negative” if no rare variant was identified in genes unequivocally associated with 
non-syndromic LQTS (KCNQ1, KCNH2, SCN5A, CALM1-3 and TRDN).[17–19] A rare variant 
was defined as a protein sequence altering (i.e. missense, nonsense, frameshift deletion, in-
frame deletion, large deletion and duplication) or splice-site variant with an allele frequency 
<1x10-4 in the Genome Aggregation Database (gnomAD).[20–22] Genetic testing and variant 
curation as per the American College of Medical Genetics and Genomics and Association of 
Molecular Pathology (ACMG/AMP) guidelines[23] was conducted as in the Supplementary 
Methods. All subjects or their guardians provided informed consent, and the study was 
approved by the appropriate ethical review boards. 
 
Phenotypic characterization and measurement of the QT interval  
Clinical data were collected at each of the participating centres. We collected a baseline ECG 
for each patient, preferably not during beta-blocker use. The QT-interval duration was 
measured as previously described (Figure I in the Supplement, Supplementary 
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Methods).[24] In genotype negative patients, a LQTS diagnosis was additionally curated by 2 
clinicians (NL, RT) and in case of uncertainty, two senior LQTS experts (AAW, PJS) were 
consulted. As per international guidelines[5], we only included genotype negative patients with 
a LQTS risk score ³3.5 or with a resting QTc ³ 500ms in repeated 12-lead ECGs, in the 
absence of a secondary cause for QT prolongation.  
 
Genome-wide array genotyping, quality control and imputation 
We performed genome-wide genotyping for all European cases on the Illumina 
HumanOmniExpress array and for all Japanese cases on the Illumina Global Screening Array. 
Genotypic data of 8,219 control individuals of European ancestry and 1,671 individuals of 
Japanese ancestry were obtained from different cohorts (Table II in the Supplement). Quality 
control (QC)[25], imputation and association analysis were performed separately in the 
European and Japanese datasets. All genetic variants were mapped to and reported using 
Genome Reference Consortium Human genome build 37 (GRCh37). 
After QC (see Supplementary Methods for details), we performed genome-wide 
imputation using Eagle2 phasing, Minimac3 and the Haplotype reference consortium 
(HRCr1.1) panel implemented on the Michigan Imputation Server for both the European and 
Japanese datasets.[26] After imputation, only single nucleotide polymorphisms (SNPs) with 
MAF>0.01 and a Minimac3 imputation score of R2>0.3 were included in further analyses. 
 
Genome-wide association analysis  
We performed genome-wide association analyses to assess the role of common variants in 
LQTS susceptibility (case-control) and severity (QTc within the cases). Case-control 
association of alternate allele dosage with LQTS was performed using logistic regression 
correcting for genotypic PC 1-10. Quantitative trait analyses for QTc were conducted using a 
linear regression model correcting for age, beta-blocker use at ECG, LQTS type ([KCNQ1 
(LQT1), KCNH2 (LQT2) and SCN5A (LQT3), or genotype negative), sex, and PC 1-10. 
Genome-wide association analyses were carried out separately for the European and 
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Japanese LQTS cohorts, followed by meta-analysis using an inverse variance weighted fixed 
effect model, implemented in METAL (version 2011-03-25).[27] Genome-wide statistical 
significance and suggestive thresholds were set to P<5x10-8 and P<1x10-6, respectively. 
Summary statistics were uploaded to FUMA (Functional Mapping and Annotation of GWAS) 
for generation of Manhattan, quantile-quantile and regional association plots for risk loci.[28] 
 
Survival analyses 
Time to life-threatening arrhythmic events (LAE) survival analyses were performed in the LQTS 
cases. Follow up started at birth and stopped at the date of a document LAE, the last visit or 
the 41st birthday, whichever came first. LAE were defined as out of hospital cardiac arrest 
(OHCA) or hemodynamically unstable ventricular tachycardia/ventricular fibrillation (VT/VF) or 
appropriate implantable cardioverter-defibrillator (ICD) therapy. The effect of genotype positive 
versus genotype negative status was estimated using Cox proportional hazards regression 
with/without adjustment for classic risk factors, i.e. sex and QTc ³ 500 ms. To examine possible 
differences in effect of these well-recognized risk factors in genotype positive and genotype 
negative LQTS cases, interactions between these risk factors and genotype status were 
included in the model. In addition, puberty and a sex × puberty interaction were included to 
model the modifying effect of puberty on the effect of sex. Puberty was included as time-varying 
covariate and the age of puberty was set at 16 years in both sexes (i.e. during the follow up 
period prior to the age of 16, puberty was coded as 0, whereas puberty was coded as 1 during 
the remainder of the follow up period). Kaplan Meier curves were created to illustrate the 
cumulative event free survival and log rank tests were used to compare the survival curves. 
 
Polygenic risk scores (PRS) 
For all cases and controls, we calculated a weighted QT polygenic risk score (PRSQT) 
comprising 68 SNPs that had been associated with the QT-interval in the general population 
at genome-wide statistical significance, in a study primarily including Europeans.[29] All 68 
SNPs were included in the European dataset analyses whereas only 60/68 SNPs were well-
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imputed and included in the Japanese dataset analyses (Table III in the Supplement). PRSQT 
was calculated by multiplying the alternate allele dosage by the associated effect size (β) in 
the published QT GWAS for each of the 68 SNPs. Then, the PRSQT was normalized to a mean 
of 0 and standard deviation of 1. We used logistic regression to test for association of PRSQT 
with case-control status, correcting for PC 1-10. We also used P-value thresholding and R2 
pruning with P-values of 5x10-8, 1x10-5, 1x10-4 and 1x10-3, 1x10-2 and R2 of 0.2 and 0.1 on 
summary statistics from a European[29] and Japanese[30] descent general population QT-
interval GWAS. The resulting 10 models were used to calculate a European and Japanese 
PRSQT. The association of PRSQT with LQTS was assessed using a logistic regression for the 
European and Japanese cases separately. The best model was selected based on the 
maximal C-statistic, as recently performed.[31] No other covariate was used to avoid model 
overfitting. 
The odds ratios (ORs) associated with quartile 2, 3 and 4 were calculated using the 
first PRSQT quartile as the reference. The association of PRSQT and known QT predictors with 
QTc was performed using a univariable linear regression followed by multivariable analysis, 
including in the final model only those variables with a P<0.05 in the univariable analyses. The 
association of PRSQT quartiles with time to life-threatening arrhythmic events (LAE) was 
assessed using Cox proportional hazards regression with/without adjustment for classic risk 
factors.  Association analyses of PRSQT with case-control status, QTc and time to LAE were 
performed separately in the European and Japanese datasets, followed by a fixed-effects 
model meta-analysis. 
 
Common variant heritability 
We used the generalized restricted maximum likelihood (GREML) approach of GCTA[32] to 
estimate how much of the variance in LQTS susceptibility could be attributed to common 
genetic variants (SNP-based heritability, h2SNP). Prior to heritability estimation, we conducted 
additional stringent genetic QC, as previously suggested (see Supplementary Methods).[33] 
We estimated the SNP-heritability on the liability scale assuming a 0.04% prevalence with 
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PC1-10 as covariates.[1] We assessed the robustness of heritability estimates from GCTA-
GREML using the generalized restricted maximum likelihood (REML) and PCGC (phenotype-
correlation genotype-correlation) regression[34] analyses implemented in LDAK[35]. We 
estimated h2SNP in the overall LQTS and genotype positive LQTS dataset in the both European 
and Japanese ancestries. Because of small sample size we were not able to estimate h2SNP in 
genotype negative LQTS patients using the approaches implemented in GCTA or LDAK. 
 
Genetic correlation with other traits 
We used bivariate LD score regression[36] to evaluate the genetic correlation between LQTS 
susceptibility (as obtained in the European descent case-control GWAS) and other cardiac 
electrical traits[2], namely PR, QRS, QT, heart rate (HR) at rest, HR in response to exercise 
and recovery, and atrial fibrillation (AF) (see Supplementary Methods for origin of summary 
statistics). We used Bonferroni correction to account for multiple testing (P = 0.05 / 7 = 0.0071). 
We did not constrain the bivariate regression intercepts in any of these analyses given the 
potential for (modest) sample overlap and population stratification. 
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RESULTS 
 
Clinical characteristics of the case cohort 
Demographic and clinical characteristics of the unrelated LQTS cases are presented in Table 
IV of the Supplement separately for the European and Japanese datasets and in Table 1 for 
the combined cohort. We included a total of 1,781 unrelated LQTS patients of European 
(n=1,344, mean QTc ± standard deviation (SD): 484±48ms) and Japanese descent (n=437, 
QTc: 485±49ms). A total of 1584 cases (89%) were genotype positive, carrying a rare variant 
in KCNQ1 (LQT1, n=800), KCNH2 (LQT2, n=661), or SCN5A (LQT3, n=123), while in 197 
(11%) no disease causing variant was identified (i.e. genotype negative) despite extensive 
genetic testing.  
The mean QTc interval in genotype negative cases was higher in comparison to 
genotype positive ones (500±52ms vs. 482±47ms, P=2x10-5) and in genotype negative cases 
a family history of SCD <50 years in 1st and 2nd degree relatives was less frequent compared 
to genotype positive ones (12.7% vs. 22.9%, P=0.001). Of the 1584 genotype positive cases, 
1333 (84%) carried an ACMG pathogenic or likely-pathogenic variant and the remainder had 
a VUS. The QTc did not significantly differ between carriers of VUS and those with a 
pathogenic or likely pathogenic variant (P=0.9). 
In total, 429 cases (24%) had a life-threatening arrhythmic event (LAE) at a median age 
of 28 [17-46] years, with 295 cases (17%) having such an event by age 40. LAE-free survival 
did not significantly differ between genotype negative and positive cases (P=0.8) or between 
European and Japanese cases (P=0.053) (Figure 1). In a multivariable Cox proportional 
hazard model, male sex (OR 1.9; P=0.004), QTc>500ms (OR 1.8; P=4x10-6) and Japanese 
ancestry (OR 1.4; P=0.03) were independent risk factors for LAE (Table V in the 
Supplement). We found a significant sex-puberty interaction (P=1x10-6), where males were at 
higher risk of LAE in the pre-pubertal years but lower risk thereafter (Figure II in the 
Supplement). The effect of the conventional risk factors sex (Pinteraction=0.3) and QTc ≥ 500ms 
(Pinteraction=0.7) did not differ between genotype positive and genotype negative cases. 
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Genotype (KCNQ1, KCNH2, SCN5A or negative) significantly affected time to LAE (Logrank 
test P<0.001; Figure III in the Supplement). Cases with a rare variant in KCNQ1 had a lower 
risk of LAE compared to KCNH2, SCN5A and genotype negative ones (P<0.01 for all 
comparisons). None of the other post-hoc pairwise comparisons reached statistical 
significance. Time to LAE did not differ between cases with a VUS and those with pathogenic 
or likely pathogenic variant (Figure IV in the Supplement). 
 
Case-control GWAS 
We conducted a case-control GWAS separately in European (1,238 cases vs. 8,219 controls, 
genomic test inflation (l) =1.024) and Japanese (418 cases vs. 1,617 controls, l=1.034) cases 
using ancestry-matched controls (Figure V and VI in the Supplement), followed by 
transethnic meta-analysis (l=1.028). This uncovered 3 loci reaching the threshold for genome-
wide statistical significance (Table 2, Figure 2, Figure VII and VIII in the Supplement). The 
most significant association was obtained for rs12143842 (OR=1.32, 95% confidence interval 
(CI): 1.21-1.42, P=1.09x10-11) located upstream of NOS1AP (Figure VIII-a in the 
Supplement). The lead SNP at the second locus was located in an intron of KCNQ1 
(rs179405, OR=1.38, 95%CI: 1.23-1.54, P=1.92x10-8 (Figure VIII-b in the Supplement). At 
the third locus, the lead SNP, rs17061696 (OR=1.25, 95%CI: 1.15-1.35, P=4.33x10-8), was 
located in an intron of KLF12 (Figure VIII-c in the Supplement). All three loci had been 
previously associated with the QT-interval duration, a measure of myocardial repolarization on 
the electrocardiogram (ECG), in the general population (Table 1).[29] The low-frequency 
missense variant in KCNE1, p.Asp85Asn (rs1805128, OR=2.78, 95%CI: 1.67-3.90, 
P=5.31x10-7, Figure VIII-d in the Supplement) reached the suggestive statistical significance 
threshold in the European case-control analysis. This variant, which is rare and not well 
imputed in the Japanese dataset (MAF=0.001; R2<0.3), has the largest reported effect size 
among the 68 independent SNPs (hereafter referred to as ‘QT-SNPs’) previously associated 
with QT-interval in the general population (7.4ms increase per minor allele).[29] Of note, The 
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KCNE1-p.Asp85Asn variant had a more pronounced effect in genotype negative (OR=7.64, 
95%CI: 3.66-15.95, P=5.99x10-8) than in genotype positive LQTS (OR=2.28, 95%-CI: 1.46-
3.54, P=2.59x10-4). 
 
Genetic overlap between LQTS and QT-interval in the general population 
The identification of SNPs previously associated with QT-interval in the general population is 
in line with the fact that QT-interval prolongation on the ECG (representing prolonged cardiac 
repolarization) is the central intermediate phenotype underlying LQTS. In fact, 23 of the 68 QT-
SNPs previously associated with QT-interval in the general population, were associated with 
LQTS at nominal significance (i.e. P<0.05), while only 4 would be expected under the null 
hypothesis (Table VI in the Supplement). We observed a strong positive correlation between 
the effect that each of the 68 QT-SNPs had on the QT-interval in the general population[29] 
and the risk they conferred for LQTS in the current study; this effect was consistent across 
both the European (Figure 3a; R2=0.67; P=2.04x10-17) and the Japanese (Figure 3b; R2=0.52; 
P=1.43x10-10) datasets. Overlap between genetic risk for LQTS and genetic determinants of 
the QT-interval in the general population[29] was further demonstrated by genome-wide 
bivariate LD score regression[36], which detected a significant positive genetic correlation 
(rg=0.40, SE=0.14, P=3.2x10-4) between these phenotypes. No significant correlation was 
found for other cardiac electrical traits (Figure IX in the Supplement). 
 
Analysis of PRSQT in LQTS disease susceptibility 
We then tested the aggregate effect of the 68 QT-SNPs (PRSQT) on susceptibility to LQTS by 
means of polygenic risk score (PRS) analysis (Table III in the Supplement). PRSQT was 
significantly associated with a diagnosis of LQTS in the European set, the Japanese set and 
in the meta-analysis of both datasets (Figure 4a and 4c; Table 3; meta-analysis b=0.34, 
SE=0.03, P=1.1x10-38, heterogeneity P=0.15). Similar results were obtained when we excluded 
common variants located at the known Mendelian LQTS loci from the PRS (Table VII in the 
Supplement). Ten different PRS derived by the pruning and thresholding method on summary 
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statistics from the European descent general population QT-interval GWAS did not significantly 
outperform the PRSQT in discriminating case-control status (Table VIII-a in the Supplement). 
Similarly, Japanese ancestry-specific PRS derived from summary statistics of a small 
Japanese QT-interval GWAS[30] had less discriminative accuracy in the Japanese case-
control dataset compared to the European-derived PRSQT, likely due to the small size of the 
Japanese QT-interval GWAS  (Table VIII-b in the Supplement). 
We next explored whether the genetic architecture of genotype negative patients (i.e. 
those lacking a rare variant after extensive genetic testing of the established LQTS disease 
genes) differed from that of genotype positive patients. This was done by comparing PRSQT 
between both groups, uncovering a significantly higher PRSQT in genotype negative patients, 
pointing to a more prominent role for common variants in disease susceptibility in these 
patients. This effect was consistently observed in both the European (P=5.1x10-6, Figure 4b) 
and the Japanese (P=2.0x10-3, Figure 4d) datasets (Table 3). Similar results were obtained 
in a sensitivity analysis correcting for QT-interval, ensuring that enrichment of QT prolonging 
alleles in the genotype negative patients was not driven by differences in QT-interval 
(P=7.4x10-5 in Europeans; P=2.6x10-3 in Japanese, Table 3). These associations remained 
statistically significant when we restricted the analysis to patients with a pathogenic or likely 
pathogenic variant according to American College of Medical Genetics and Genomics and 
Association of Molecular Pathology (ACMG/AMP) guidelines (i.e. excluding cases with a rare 
variant of unknown significance (VUS); Supplementary Methods, Table IX and X in the 
Supplement). Increasing PRSQT quartiles were associated with a significantly higher disease 
susceptibility for genotype negative LQTS compared to the lowest quartile (Figure 5, Table XI 
in the Supplement). Notably, using a PRSQT percentile threshold of 80, 90 and 95, individuals 
above the threshold compared to those below have an OR [95%CI] of 2.9 [2.2-4.0], 4.1 [2.9-
5.8] and 5.7 [3.9-8.4], respectively, for genotype negative LQTS. Of interest, the higher PRSQT 
in genotype negative patients compared to genotype positive patients was reflected by the 
larger difference in PRSQT between genotype negative patients vs. controls (Table 3; meta-
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analysis b=0.735, SE=0.074, P=2.24x10-23) compared to genotype positive vs. controls (Table 
3; meta-analysis b=0.294, SE=0.028, P=1.09x10-25). 
 
Common variant heritability of LQTS 
To evaluate the proportion of variance in LQTS susceptibility explained by common genetic 
variants (h2SNP) we used the generalized restricted maximum likelihood (GREML) approach of 
GCTA.[32,37] Assuming a disease prevalence of 0.04%,[1] the SNP heritability estimate on 
the liability scale was h2SNP = 0.148 (SE=0.019, 95%-CI: 0.111-0.185, P=5.0x10-18) in the 
overall European LQTS dataset. h2SNP was similar when the analysis was restricted to 
genotype positive LQTS patients. Similar results were also observed in the Japanese dataset 
and when using the PCGC (phenotype-correlation genotype-correlation) regression[34] and 
the GREML estimation implemented in LDAK[35], as well as when we restricted h2SNP analyses 
to only patients with a pathogenic or likely pathogenic variant (Table XII in the Supplement). 
 
Association of single SNPs and PRSQT with LQTS severity 
To identify genetic modifiers of disease severity we conducted a GWAS for QT-interval within 
the LQTS cases which did not uncover any genome-wide significant loci (Figure X in the 
Supplement). None of the 68 SNPs previously associated with QTc in the general 
population[29] showed association with QTc after Bonferroni correction. PRSQT showed a 
weak positive correlation with QTc in the European cases (correlation coefficient [r]=0.06; 
P=0.042; Figure XI in the Supplement). In a multivariable linear regression model including 
clinical covariates associated with QTc (age at ECG recording, LQTS type and sex), PRSQT 
was not significantly associated with QTc (Table XIII in the Supplement). Similarly, in a sub-
analysis restricted to probands (comprising 97% of the total of unrelated LQTS cases) using 
the multivariable linear regression model, PRSQT was not significantly associated with QTc 
(data not shown). In exploratory subgroup analyses, PRSQT was independently associated 
with QTc in KCNH2 rare variant carriers but not in KCNQ1 rare variant carriers (Table XIII in 
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the Supplement). This result was not replicated in the Japanese LQTS dataset. PRSQT was 
not significantly associated with time to LAE in neither Europeans nor Japanese cases (Figure 
XII in the Supplement). 
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DISCUSSION 
 
Our findings establish an important role for common genetic variation in LQTS susceptibility 
and support a complex (polygenic) architecture in genotype negative LQTS. Case-control 
GWAS identified 3 genome-wide significant risk loci near NOS1AP, KCNQ1 and KLF12. 
Heritability analysis demonstrated that ~15% of LQTS disease liability is attributable to 
common genetic variation. Polygenic risk score analysis testing the aggregate effect of SNPs 
previously associated with QT interval in the general population (PRSQT) identified a higher 
PRSQT in LQTS cases compared to controls and higher PRSQT in genotype negative vs. 
genotype positive LQTS. 
 
Shared genetics of LQTS and QT interval in the general population  
The case-control GWAS uncovered three genetic LQTS susceptibility loci at genome-wide 
statistical significance near NOS1AP, KCNQ1 and KLF12, and one missense variant in KCNE1 
at the suggestive threshold (Figure 2). The association of SNPs at KCNQ1 points to the 
involvement of common variants acting alongside rare variants in these genes in mediating 
disease susceptibility, akin to what was previously reported for common and rare variation in 
and around the SCN5A gene in Brugada syndrome.[16] All 4 risk loci had been previously 
implicated in genetic control of the QT interval by GWAS in the general population.[29] For the 
68 SNPs associated with QT interval in the general population, we noted a strong positive 
correlation between their effect on QT interval (obtained in the general population) and their 
odds ratio for LQTS susceptibility, indicating, as expected, that the larger the effect a SNP has 
on the QT interval, the more it increases LQTS susceptibility (Figure 3). The strong genetic 
correlation between LQTS susceptibility and QT interval in the general population provides 
quantitative support for genetic overlap (Figure IX in the Supplement).  
The association with the highest effect in the case-control GWAS was found for the 
p.Asp85Asn missense variant in KCNE1 (rs1805128). This variant increased susceptibility for 
LQTS in the overall cohort, but had a more prominent effect in genotype negative LQTS with 
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an odds ratio of ~7 (versus an odds ratio of 2 in genotype positive patients). This variant has 
an allele frequency of ~1.2% in non-Finnish Europeans, and ~0.5% in East Asians and has the 
largest effect size on the QT in the general (European descent) population (7.42 ms per minor 
[Asn] allele).[29] It has been shown to be enriched in patients with drug-induced torsades de 
pointes[38]. 
 
Genetic architecture of genotype positive LQTS 
LQTS has traditionally been seen as a monogenic disorder mostly attributed to a rare variant 
with a drastic effect on ion channel function. We now demonstrate that a considerable extent 
(~15%) of disease liability is attributable to common genetic variation. In genotype positive 
LQTS families, where the penetrance of pathogenic variants may be low for certain variants[8], 
the contribution of common variants to disease susceptibility may also contribute to variable 
disease penetrance. It has been well established that LQTS probands have a longer QT 
interval and greater arrhythmic risk compared to family members carrying the same 
variant.[7,13,39] This observed increased penetrance in probands may result from a greater 
burden of common QT-prolonging variants compared to other, less-severely affected or 
unaffected mutation-carriers. However, since this study was comprised of only unrelated 
patients, this remains to be determined. Whether the PRSQT could discriminate between 
affected vs. unaffected mutation carrier family members is intuitive appealing but remains to 
be formally demonstrated. 
 
Genotype negative LQTS: A polygenic subtype of LQTS? 
Polygenic risk score analysis testing the aggregate effect of SNPs previously associated with 
QT interval in the general population (PRSQT) identified a higher PRSQT in genotype negative 
vs. genotype positive patients. This observation points to genotype negative LQTS, comprising 
~10% of LQTS patients, as a polygenic subtype of the disorder where the underlying etiology 
involves, at least in part, a high burden of common QT prolonging alleles. As such, genetic 
susceptibility in genotype negative patients may not be determined to a large extent by one 
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strong genetic factor as occurs in genotype positive patients, but results from the accumulation 
of multiple variants (polygenic inheritance). The lower rate of family history of SCD in genotype 
negative LQTS patients is in line with polygenic inheritance. Our observations corroborate 
findings in other heritable phenotypes, such as familial hypercholesterolemia (FH), where 
patients without a disease-causing variant in the LDLR, APOB and PCSK9 genes have a 
higher PRS based on LDL modulating variants in comparison to those with rare FH causing 
genetic variants.[40] As such, the accumulation of multiple discrete common variants may 
confer risk similar to a monogenic mutation. This was recently demonstrated for common 
disorders such as coronary artery disease and atrial fibrillation, where individuals at the upper 
extreme of the PRS distribution had a risk of developing the disease reportedly comparable to 
carriers of a monogenic mutation.[31] The overlap in the PRSQT distributions among genotype 
negative LQTS cases and controls (Figure 4) suggests that other factors are involved, possibly 
including low-frequency genetic variants with intermediate effect sizes as well as other 
common variants with smaller effect sizes. 
In addition to providing insight into the genetic architecture of genotype negative LQTS, 
we here also describe for the first time the natural history in these patients. All ~200 genotype 
negative LQTS patients met diagnostic criteria for definite LQTS (i.e. QTc>500ms or LQTS 
score ≥3.5) and underwent sequencing of the unequivocal non-syndromic LQTS genes. 
Patients with genotype negative LQTS had a higher QTc in comparison to LQT1-3 patients but 
similar event-free survival as their genotype positive counterparts (Figure 1). The effect of 
established clinical risk factors, i.e. sex and QTc-duration, did not significantly differ between 
genotype positive and negative (no interaction effect) suggesting they may also be used to 
stratify risk of events in genotype negative LQTS. 
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Common variants do not contribute to LQTS severity within probands 
We sought to identify genetic modifiers of LQTS. In contrast to the case-control GWAS, GWAS 
for QTc and arrhythmic events within the unrelated LQTS cases did not uncover any genome-
wide significant locus. PRSQT was also not significantly associated with QTc nor with the 
occurrence of events. At first glance, this may seem contradictory to previous studies in LQTS 
that demonstrated a modulatory effect of SNPs at NOS1AP on the QTc and arrhythmic 
events[10,11,13], as well as a study in the general population that showed a modulatory effect 
of PRS derived from prior GWAS on QT-interval.[41] For example, a study we previously 
conducted in LQT2 patients uncovered strong associations with large effect sizes (>12 
ms/allele) for SNPs at NOS1AP.[13] An important difference however, is that the current study 
did not include family members but only one patient per family (97% probands), whereas the 
previous studies considered both probands and genotype positive relatives. Conceptually, 
inclusion of both probands and relatives results in greater variation in QTc and is thus expected 
to increase statistical power for detection of modulatory effects. Moreover, the different rare 
variants in the patients we studied here are associated with biophysical defects of varying 
severity. As such, they are also expected to contribute to interindividual variability which is 
difficult to account for. For instance, LQT2 patients with pore-region variants are known to be 
more severely affected than other LQT2 patients.[42] Indeed, in a sub-analysis, restricted to 
European LQT2 patients, where we accounted for the mutation location (pore versus non-
pore), we detected an association of PRSQT with QTc. In sum, our data show that common 
variants do not affect disease severity across all probands studied. Further studies are needed 
to explore their predictive role in family members. 
 
Potential clinical implications 
In genotype negative LQTS, disease susceptibility estimation for relatives does not follow a 
Mendelian pattern. In our cohort, a positive family history of SCD was less often observed in 
genotype negative individuals compared to genotype positive ones, suggesting that risk for 
family members in genotype negative patients may be lower. Polygenicity in genotype negative 
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individuals implies that risk is not primarily attributable to one genetic factor inherited from one 
of the biological parents as is the case for autosomal dominant LQTS. In such cases, cascade 
screening may necessitate clinical evaluation of both maternal and paternal family members. 
Future clinical utility of genetic testing based on polygenic inheritance necessitates the 
availability of polygenic risk scores with high discriminative capacity. The discriminative 
capacity of a PRS based on QT modulating SNPs is expected to improve as knowledge 
concerning variants that modulate the QT interval become known, for example through larger 
GWAS studies, or by combining it with non-genetic modifiers. In a recent study, a PRS based 
on 61 QT SNPs (a subset of the 68 QT modulating SNPs included in the PRSQT used herein) 
explained a substantial proportion of QT interval response to QT prolonging drugs in a trial of 
3 QT-prolonging drugs conducted in healthy individuals, as well as risk of torsade de pointes 
in a case-control study.[43] This provides further support to a liability threshold model whereby 
multiple factors, genetic and non-genetic, impact on cardiac repolarization and determine 
arrhythmic risk. In this respect, calculation of PRSQT for the purpose of preventive avoidance 
of QT-prolonging drugs may be desirable for relatives of genotype negative LQTS. Clearly, 
further studies are needed to address how testing for polygenic susceptibility may become 
clinically useful.  
 
Study limitations 
Although in genotype negative LQTS patients we performed sequencing of the coding region 
of non-syndromic LQTS genes, this may have missed copy number variation or disease-
causing variants in the non-coding region[44] of established genes as well as mutations in yet 
unknown disease genes. This may have blunted the differences between genotype negative 
and genotype patients and thus would not affect the study conclusions. Despite being the 
largest international dataset of unrelated LQTS patients published to date, the study had limited 
statistical power to detect lower effect associations at GWAS significance threshold. The 
prespecified design of meta-analysing European and Japanese GWAS may also miss disease 
loci with differences in haplotype structure among European and East Asian chromosomes. 
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Nonetheless, GWAS in separate ancestries did not detect any association at GWAS threshold. 
Finally, studies in larger patient sets are required to further refine our understanding of the 
genetic architecture underlying LQTS in genotype negative patients. 
 
Conclusion 
This work establishes an important role for common genetic variation in susceptibility to LQTS. 
Common genetic variation affecting the QT interval in the general population contributes to 
disease susceptibility in both genotype positive and genotype negative LQTS. The role of 
common variants is predominant in genotype negative LQTS, suggesting that the latter may 
constitute a polygenic form of LQTS. Increasing burden of QT-prolonging common variants 
(e.g. PRSQT) is associated with higher susceptibility for LQTS but is not associated with disease 
severity within LQTS probands. Further studies are needed to assess the role of polygenic risk 
within LQTS families. 
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Figure 1 | Kaplan-Meier LAE-free survival curves stratified by ancestry 
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Figure 1 | Kaplan-Meier LAE-free survival curves stratified by ancestry. EU and JP refer to European and Japanese LQTS cases, 
respectively. Geno+ and Geno- refer to genotype positive and genotype negative LQTS cases, respectively. LAE, life-threatening arrhythmic 
event defined as the composite of out of hospital cardiac arrest or hemodynamically unstable ventricular tachycardia/fibrillation. Logrank test 
P=0.3.  
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Figure 2 | Manhattan plot of LQTS case-control meta-analysis 
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Figure 2 | Manhattan plot of LQTS case-control meta-analysis. Manhattan plot displaying the base-pair position of each of the tested SNPs 
(each dot represents an individual SNP) along the chromosomes on the x axis and the corresponding -log10 transformed association P value on 
the y axis. The association P-values from the meta-analysis of the two GWAS conducted separately in European and Japanese cases and 
controls, respectively, are displayed. The upper and lower dashed lines indicate the genome-wide significance (P<5x10-8) and suggestive 
significance (P<1x10-6) thresholds, respectively. SNPs at genomic regions that reached the genome-wide or suggestive significance thresholds, 
are marked in red, whereas SNPs from other regions are marked in black or grey. The association for variant rs1805128 (KCNE1:p.Asp85Asn) 
is solely driven by the European analysis since it is not well imputed and rare (R2<0.3. MAF=0.001) in the Japanese dataset. 
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Figure 3 | Correlation of effect size of QT-associated SNPs with their effect size in LQTS GWAS 
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Figure 3 | Correlation of effect size of QT-associated SNPs with their effect size in LQTS GWAS. The x-axis represents the effect estimates 
from the QT-interval GWAS conducted in the general population (milliseconds per alternative allele) and the y-axis the effect of each of these QT-
interval associated alleles on disease risk of LQTS [Ln(OR)] in the European (A, blue) and Japanese (B, red) datasets. All 68 SNPs associated 
with QT in the general population were assessed in Europeans, whereas 60 SNPs were properly imputed in the Japanese dataset. In the LQTS-
GWAS meta-analysis, 23/68 SNPs previously associated with the QT in the general population reached nominal significance (see Supplementary 
Table 6). Loci that reached genome-wide significance in the LQTS cases-control transethnic meta-analysis (NOS1AP-rs12143842, KCNQ1-
rs179405 and KLF12-rs728926) and KCNE1-rs1805128 are identified with text. 
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Figure 4 | Distribution of PRSQT in controls, all LQTS and genotype positive and negative subgroups 
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Figure 4 | Distribution of PRSQT in controls, LQTS and genotype positive and negative subgroups. The X-axis represents the QT polygenic 
score (PRSQT) in the European (A-B, blue) and Japanese (C-D, red) LQTS case-control datasets. In A and C, all LQTS cases are grouped 
regardless of whether they are genotype positive or negative, whereas in B and C cases have been stratified in genotype positive and negative 
LQTS subgroups. PRSQT was normalized to a mean of 0 and standard deviation of 1. Reported P values refer to the effect of PRSQT in a logistic 
regression correcting for the first 10 principal components. *Refers to case-control association. Comparison of PRSQT between genotype negative 
vs. genotype positive LQTS uncovered a significantly higher PRSQT in genotype negative patients. This effect was consistently observed in both 
the European (P=5.1x10-6, Figure 4b) and the Japanese (P=2.0x10-3, Figure 4d) patients (Table 3). 
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Figure 5 | Increasing genotype negative LQTS risk with increasing PRSQT quartiles 
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Figure 5 | Increasing LQTS risk with increasing PRSQT quartiles. Odds ratio (OR) for genotype negative LQTS (filled circles) and 95% 
confidence intervals (vertical bars) associated with each PRSQT quartile taking the first PRSQT quartile as the reference. Data shown correspond 
to a meta-analysis of effects computed separately in the European and Japanese datasets. P-values refer to comparison of each quartile against 
the first quartile. 
  
 41 
Table 1 | Clinical characteristics of all unrelated LQTS cases 
Parameter 
Genotype positive 
(n=1584) 
Genotype negative 
(n=197) 
Male, no. (%) 584/1584 (37) 76/197 (39) 
QTc mean ± SD, ms 482±47 500±52 
Genotype, no. (%)     
KCNQ1 800/1584 (50) - 
KCNH2 661/1584 (42) - 
SCN5A 123/1584 (7.8) - 
Syncope, no. (%) 722/1584 (46) 75/197 (38) 
LAE (OHCA or VF/VT) before age 41, no. (%) 262/1578 (17) 33/196 (17) 
Age at first LAE, median [IQR] 21 [13-29] 26 [16-35] 
Treatment during follow-up, no. (%)     
Beta-blocker 1169/1487 (79) 124/168 (74) 
ICD 277/1562 (18) 38/172 (22) 
PM 50/1565 (3.2) 11/171 (6.4) 
LCSD 29/1583 (1.8)  1/171 (0.6) 
Family history of SCD <50 years of age, no. (%) 323/1409 (23) 24/189 (13) 
 
Table legend:  
ICD, implantable cardioverter-defibrillator; IQR, interquartile range; LAE, life-threatening arrhythmic event; LCSD, left cardiac sympathetic 
denervation; OHCA, out of hospital cardiac arrest; PM, pacemaker; SCD, sudden cardiac death, SD, standard deviation; VF/VT, 
hemodynamically unstable ventricular fibrillation/tachycardia 
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 Table 2 | Significant loci in LQTS case-control GWAS 
 
Table legend: 95%CI, 95% confidence interval; AAF, alternative allele frequency; GRCh37, genomic position on build GRCh37; OR, odds ratio 
per alternative allele. * QT increase (in ms) per alternative allele in the general population, # The lead SNP at the KCNQ1 locus (rs179405) is in 
linkage disequilibrium (LD) with rs7122937 (R2=0.497) which had been previously associated with QT-interval in the general population (1.9 ms 
increase per risk allele).  
     
Meta-analysis European Japanese  
Lead SNP GRCh37 Alternative 
allele 
Reference 
allele 
Closest 
gene 
OR 95%CI P AAF 
(controls 
/cases) 
OR P AAF 
(controls 
/cases) 
OR P Effect 
on 
QT 
(ms) * 
rs12143842 1:162033890 T C NOS1AP 1.31 1.21-1.42 1.09E-11 0.26/0.32 1.29 7.34E-08 0.38/0.47 1.41 2.13E-05 3.5 
rs179405 11:2525395 A G KCNQ1 1.38 1.23-1.54 1.92E-08 0.14/0.17 1.34 4.03E-06 0.10/0.14 1.63 5.42E-04 1.9# 
rs17061696 13:74511991 C G KLF12 1.25 1.15-1.35 4.33E-08 0.37/0.43 1.27 8.91E-08 0.19/0.21 1.16 1.43E-01 0.58 
 43 
Table 3 | Association of PRSQT with LQTS 
 
  European  Japanese  Meta-analysis 
Association analysis of PRSQT  n ! SE P n ! SE P n ! SE P 
All LQTS vs. Controls 1,238/ 
8,219 
0.322 0.030 4.93E-26 418/ 
1,671 
0.412 0.055 6.16E-14 1,656/ 
9,890 
0.343 0.0263 1.08E-38 
Genotype positive LQTS vs. 
Controls 
1,115/ 
8,219 
0.277 0.032 3.47E-18 356/ 
1,671 
0.348 0.058 2.52E-09 1,471/ 
9,890 
0.294 0.028 1.09E-25 
Genotype negative LQTS vs. 
Controls 
123/ 
8,219 
0.733 0.090 3.74E-16 62/ 
1,671 
0.740 0.129 1.19E-08 185/ 
9,890 
0.735 0.0738 2.24E-23 
Genotype negative vs.  
Genotype positive LQTS 
123/ 
1,115 
0.447 0.098 5.05E-06 62/ 
356 
0.401 0.129 2.01E-03 185/ 
1,471 
0.430 0.078 3.54E-08 
Genotype negative vs.  
Genotype positive LQTS* 
123/ 
1,115 
0.409 0.103 7.36E-05 62/ 
356 
0.393 0.130 2.62E-03 185/ 
1,471 
0.403 0.0807 6.05E-07 
 
Table legend: b, regression coefficient; n, sample size (cases/controls); P, P value; SE, standard error; *Correcting for QTc
 44 
URLs 
LDAK: http://dougspeed.com/ldak 
LD score regression: https://github.com/bulik/ldsc 
FUMA: http://fuma.ctglab.nl 
PLINK: https://www.cog-genomics.org/plink2 
METAL: https://genome.sph.umich.edu/wiki/METAL 
Michigan Imputation Server: https://imputationserver.sph.umich.edu 
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